KB-1282

Ponsegromab

Home » Antibody » Ponsegromab

Background

Ponsegromab (formerly PF 06946860) is a subcutaneously administered, growth differentiation factor 15 (GDF15) inhibitor, being developed by Pfizer, for the treatment of cachexia. This is a secondary reaction, mainly caused by tumor cell products and cytokines released by the body, and manifests as loss of appetite, weight loss, anemia, weakness, exhaustion, etc. About 20% of cancer patients die from cancer cachexia.

Specifications

Catalog Number:
KB-1282
Cell Line Name:
Ponsegromab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GDF15
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Lyall, D. M. et al. Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. JAMA Cardiol. 2, 882¨C889 (2017). 2.Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679¨C689 (2010). 3.Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908¨C922 (2018).
Please enable JavaScript in your browser to complete this form.